Eli Lilly to face competition in Russian insulin lispro market
The Russian drugmaker Geropharm has officially announced the completion of registration two biosimilars of insulin lispro, particularly those of ultra-short and medium-duration action, according to the company, reports The Pharma Letter’s local correspondent.
As part of the company’s plans is the beginning full cycle production of these drugs from its own pharmaceutical substances.
According to recent data, provided by the Russian pharma analytics company DSM Group, in 2018 the Russian insulin lispro market amounted to about 1.9 billion roubles ($30 million) in value and 1.2 million packages in volume terms, with almost 100% of the market being controlled by the USA’s Eli Lilly (NYSE: LLY) – the supplier of original insulin lispro.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze